SciSparc Ltd. (SPRC)

IL — Healthcare Sector
Peers: ONCS  VRAX  HILS  ZVSA  UNCY  QNRX  CDIO  PXMD  YS  CVKD  VIRI  HOTH  NLTX  CTMX  ASMB  TIL  NUVB  BWV  REVB  KPRX 

Automate Your Wheel Strategy on SPRC

With Tiblio's Option Bot, you can configure your own wheel strategy including SPRC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol SPRC
  • Rev/Share 0.645
  • Book/Share 4.415
  • PB 0.0752
  • Debt/Equity 0.0056
  • CurrentRatio 5.3631
  • ROIC -0.8127

 

  • MktCap 3401403.0
  • FreeCF/Share -2.3964
  • PFCF -0.701
  • PE -0.0976
  • Debt/Assets 0.0044
  • DivYield 0
  • ROE -0.8338

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 5
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles
SPRC
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has entered into a loan agreement with AutoMax Motors Ltd. ("AutoMax") to provide a $2 million loan (the “New Loan”). The funding will support AutoMax's business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. (“JAC”) electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4.25 …

Read More
image for news SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

About SciSparc Ltd. (SPRC)

  • IPO Date 2021-08-30
  • Website https://scisparc.com
  • Industry Biotechnology
  • CEO Mr. Oz Adler CPA
  • Employees 2

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.